Home › Colorectal Cancer › NCT06314958

Stage II/III Colorectal Cancer Recurrence

Predicting Recurrence-Free Survival in Stage III and High-Risk Stage II Colorectal Cancer After Curative-Intent Treatment

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Stage II (high-risk) or III colorectal cancer (TNM classification, 8th edition).
* Received standard diagnostic, staging, and therapeutic procedures as per local guidelines
* Received stage-specific curative-intent resection followed by adjuvant chemotherapy.
* Confirmed cancer-free survivorship confirmed at the time of study inclusion.

Exclusion Criteria:

* Lack of written informed consent.
* Development of recurrence in the first 6 months following adjuvant chemotherapy completion.
* Hereditary colorectal cancer syndromes (identified through genetic testing)
* Inflammatory bowel diseases

About the study

This study will develop an assay to predict disease recurrence in patients with stage II/III CRC after receiving adjuvant chemotherapy, using genome-wide DNA methylation.

What is being tested

• CENSURE (other)

Sponsor: City of Hope Medical Center · Participants: 400 · Started: Mar 15, 2023

Contact the study team

• Ajay Goel, PhD · Phone: 6262183452

Official record on ClinicalTrials.gov — NCT06314958

Locations in the U.S.

Conditions

• Colorectal Cancer

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.